RBC Capital has initiated coverage of Dyne Therapeutics (DYN) and Avidity Biosciences (RNA) with outperform ratings, citing ...
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
In a report released on November 24, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Avidity Biosciences (RNA – Research ...
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...
Fintel reports that on November 26, 2024, RBC Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a ...
Myotonic dystrophy is an inherited muscular dystrophy causing muscle weakness and wasting. Excessive daytime sleepiness (hypersomnia) is a frequent complaint of people with myotonic dystrophy and is ...
Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when it decided to acquire ...
Shareholders of Kate Therapeutics are entitled to receive up to $1.1 billion from the upfront payments and additional ...
In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...
Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand ...